Fig. 3: TuPro marker subset utilized in clinical decision-making.
From: Feasibility of multiomics tumor profiling for guiding treatment of melanoma
a, OncoPrint showing biomarkers (cutoff of >2%) detected by TuPro and used for treatment decisions (n = 90). Data on the technology node used to measure each marker, the cohort and class of treatment received (chemotherapy, targeted therapy, immunotherapy) are provided. b, Markers (n = 26) used for treatment decision-making in the palliative SOC cohort. c, Markers (n = 44) used for treatment decision-making in the beyond SOC cohort.
